Reports Q3 revenue $741k, consensus $500k. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China, Hong Kong, and Canada,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics (ALGS). “We are pleased with the progress to date and look forward to interim readouts in 2026. Importantly, we look forward to sharing additional pevy data next week at AASLD’s The Liver Meeting. We maintain our enthusiasm regarding the potential for pevy as well as our entire development pipeline, including ALG-055009, which is in continued discussions with potential partners for obesity and MASH.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics receives USAN council approval for pevifoscorvir sodium
- Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
- Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target